Zura Bio Limited (NASDAQ:ZURA) Insider Buys $24,999.31 in Stock

Zura Bio Limited (NASDAQ:ZURA) insider Michael Howell purchased 7,987 shares of the company’s stock in a transaction on Monday, April 22nd. The stock was acquired at an average price of $3.13 per share, with a total value of $24,999.31. Following the purchase, the insider now owns 7,987 shares of the company’s stock, valued at $24,999.31. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.

Zura Bio Price Performance

Shares of ZURA opened at $3.62 on Friday. Zura Bio Limited has a 1-year low of $2.00 and a 1-year high of $14.00. The firm has a fifty day moving average price of $3.19 and a 200 day moving average price of $4.03.

Institutional Investors Weigh In On Zura Bio

A number of institutional investors and hedge funds have recently bought and sold shares of ZURA. Lynx1 Capital Management LP purchased a new stake in Zura Bio in the third quarter valued at $65,000. Forefront Analytics LLC purchased a new stake in Zura Bio in the third quarter valued at $95,000. Bank of New York Mellon Corp purchased a new stake in Zura Bio in the third quarter valued at $224,000. Raymond James & Associates raised its holdings in shares of Zura Bio by 14.0% in the third quarter. Raymond James & Associates now owns 77,356 shares of the company’s stock valued at $511,000 after buying an additional 9,481 shares during the last quarter. Finally, Eisler Capital US LLC purchased a new stake in shares of Zura Bio in the third quarter valued at about $660,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Oppenheimer restated an “outperform” rating and issued a $16.00 price target (down previously from $17.00) on shares of Zura Bio in a research note on Monday, April 1st. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $16.40.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.